Skip to main content

Table 3 Hematological values in rats orally treated with HZJW

From: Gastroprotective and anti-Helicobacter pylori potential of herbal formula HZJW: safety and efficacy assessment

Parameter unit sex Hematological values
0 mg/kg 1000 mg/kg 2500 mg/kg 5000 mg/kg
13 wk 26 wk Recovery 13 wk 26 wk Recovery 13 wk 26 wk Recovery 13wk 26 wk Recovery
RBC 1012/L Male 9.18 ± 0.31 8.86 ± 0.47 8.65 ± 0.32 9.04 ± 0.33 8.72 ± 0.40 8.83 ± 0.45 9.27 ± 0.29 8.21 ± 0.71 8.48 ± 0.35 8.99 ± 0.80 8.94 ± 0.50 9.07 ± 0.71
Female 8.11 ± 0.28 7.90 ± 0.49 7.59 ± 0.55 8.30 ± 0.28 7.85 ± 0.69 8.01 ± 0.72 8.37 ± 0.79 7.84 ± 0.49 7.65 ± 0.41 8.58 ± 0.66 6.96 ± 1.47 7.90 ± 0.55
HGB g/L Male 174 ± 6 168 ± 6 170 ± 7 164 ± 7 166 ± 3 166 ± 3 171 ± 5 157 ± 11** 163 ± 5 168 ± 6 162 ± 6* 174 ± 8
Female 158 ± 2 162 ± 7 159 ± 10 163 ± 4 156 ± 12 167 ± 11 166 ± 10 155 ± 8 160 ± 10 166 ± 12 137 ± 29* 162 ± 4
HCT % Male 45.3 ± 1.3 43.7 ± 1.8 44.1 ± 1.8 43.9 ± 1.2 44.1 ± 1.1 43.3 ± 0.9 44.9 ± 1.3 42.2 ± 3.2 43.0 ± 1.4 44.4 ± 2.5 45.0 ± 2.4 46.5 ± 2.4
Female 40.8 ± 1.2 42.2 ± 2.3 40.7 ± 2.8 41.9 ± 1.2 41.6 ± 2.9 44.3 ± 3.1 42.2 ± 3.3 41.7 ± 2.4 41.0 ± 3.0 42.7 ± 2.6 37.8 ± 7.8 41.0 ± 1.7
MCV fL Male 49.3 ± 0.7 49.3 ± 1.2 51.0 ± 1.9 48.6 ± 1.7 50.6 ± 1.5 49.1 ± 1.6 48.4 ± 0.8 51.5 ± 1.8 50.7 ± 2.1 49.6 ± 3.3 50.3 ± 1.7 51.4 ± 1.5
Female 50.3 ± 1.4 53.5 ± 1.3 53.7 ± 2.4 50.5 ± 1.7 53.0 ± 1.7 55.4 ± 1.5 50.4 ± 0.9 53.2 ± 1.7 53.6 ± 1.3 49.8 ± 1.1 54.4 ± 1.6 52.0 ± 1.7
MCH pg Male 19.0 ± 0.2 19.0 ± 0.6 19.7 ± 0.8 18.1 ± 0.5 19.1 ± 0.7 18.8 ± 0.9 18.4 ± 0.3 19.1 ± 0.9 19.3 ± 0.7 18.8 ± 1.4 18.1 ± 0.7* 19.2 ± 0.7
Female 19.5 ± 0.7 20.6 ± 0.5 21.0 ± 0.8 19.7 ± 0.6 19.9 ± 0.7** 20.9 ± 0.8 19.9 ± 0.9 19.8 ± 0.6* 20.9 ± 0.5 19.4 ± 1.0 19.7 ± 0.9** 20.6 ± 0.9
MCHC g/L Male 385 ± 6 385 ± 7 386 ± 9 373 ± 9 376 ± 7* 383 ± 6 381 ± 4 371 ± 13* 380 ± 5 378 ± 10 361 ± 8* 374 ± 4*
Female 387 ± 8 385 ± 6 391 ± 8 389 ± 3 376 ± 7* 378 ± 8 395 ± 12 373 ± 6* 389 ± 8 389 ± 17 362 ± 16* 395 ± 7
RDW % Male 13.6 ± 0.5 13.3 ± 0.5 13.5 ± 0.4 13.7 ± 0.2 13.3 ± 0.3 13.4 ± 0.3 13.5 ± 0.3 13.3 ± 0.5 13.4 ± 0.5 13.7 ± 0.3 13.4 ± 0.4 13.4 ± 0.7
Female 13.1 ± 0.3 12.8 ± 0.3 12.6 ± 0.3 13.0 ± 0.3 12.7 ± 0.3 12.5 ± 0.2 12.9 ± 0.3 12.6 ± 0.3 12.9 ± 0.2 12.8 ± 0.3 13.0 ± 0.4 12.6 ± 0.5
PLT 109/L Male 823 ± 87 906 ± 48 881 ± 107 797 ± 106 831 ± 71 906 ± 76 816 ± 39 819 ± 74 872 ± 42 795 ± 30 854 ± 69 940 ± 99
Female 763 ± 55 756 ± 98 828 ± 60 859 ± 122 816 ± 62 936 ± 72 810 ± 45 792 ± 94 839 ± 91 848 ± 86 696 ± 271 865 ± 76
MPV fL Male 3.3 ± 0.4 3.7 ± 0.5 4.2 ± 0.7 3.3 ± 0.4 3.7 ± 0.4 4.2 ± 0.4 3.4 ± 0.4 3.9 ± 0.5 4.2 ± 0.4 3.5 ± 0.4 4.7 ± 0.5** 4.5 ± 0.6
Female 3.4 ± 0.4 3.7 ± 0.5 4.1 ± 0.9 3.4 ± 0.4 4.0 ± 0.5 4.5 ± 0.2 3.5 ± 0.2 4.0 ± 0.6 4.4 ± 0.5 3.5 ± 0.4 4.6 ± 1.6 4.0 ± 0.2
PDW % Male 14.8 ± 0.5 14.4 ± 0.3 14.3 ± 0.6 15.3 ± 0.4 14.3 ± 0.6 13.9 ± 0.2 14.9 ± 0.5 14.3 ± 0.4 14.4 ± 0.5 15.2 ± 1.0 14.3 ± 0.4 14.6 ± 0.6
   Female 15.0 ± 0.5 14.7 ± 0.3 14.4 ± 0.6 14.9 ± 0.4 14.7 ± 0.4 15.1 ± 0.8 15.3 ± 0.8 14.6 ± 0.6 14.5 ± 0.7 15.3 ± 0.6 15.2 ± 1.9 14.1 ± 0.2
PT s Male 14.4 ± 1.8 19.0 ± 5.8 15.1 ± 0.9 18.1 ± 3.9 17.1 ± 4.4 15.1 ± 0.4 13.5 ± 0.4 15.2 ± 3.2 14.7 ± 0.4 15.2 ± 2.6 15.7 ± 3.4 14.5 ± 0.6
Female 12.7 ± 0.6 13.4 ± 0.6 14.5 ± 0.5 12.4 ± 0.5 13.3 ± 0.5 14.4 ± 0.6 12.5 ± 0.3 13.7 ± 0.7 13.9 ± 0.5 12.5 ± 0.8 13.2 ± 1.0 14.1 ± 1.2
WBC 109/L Male 6.4 ± 0.4 4.6 ± 1.1 4.7 ± 1.6 8.5 ± 3.4 6.6 ± 1.2** 5.2 ± 2.1 10.5 ± 2.7** 6.1 ± 2.3 5.2 ± 0.9 11.9 ± 2.2* 6.5 ± 2.2* 5.5 ± 1.2
Female 4.3 ± 1.2 3.1 ± 0.9 2.3 ± 0.6 6.0 ± 1.4 2.8 ± 0.8 2.4 ± 0.5 6.6 ± 2.5 3.1 ± 0.8 2.3 ± 0.6 6.9 ± 1.3 2.7 ± 1.2 2.7 ± 0.6
LYM 109/L Male 5.0 ± 0.4 3.9 ± 0.9 4.1 ± 1.3 6.7 ± 3.1 5.3 ± 0.9** 4.4 ± 1.8 7.6 ± 1.8* 4.8 ± 1.8 4.3 ± 0.6 9.3 ± 2.1** 4.9 ± 1.6 4.4 ± 0.9
Female 3.5 ± 1.1 2.5 ± 0.7 1.9 ± 0.5 4.8 ± 0.8 2.2 ± 0.6 2.0 ± 0.4 5.3 ± 2.0 2.5 ± 0.6 1.9 ± 0.5 5.8 ± 1.4* 2.2 ± 1.0 2.2 ± 0.4
MON 109/L Male 0.1 ± 0.0 0.0 ± 0.1 0.0 ± 0.0 0.2 ± 0.1 0.1 ± 0.0 0.0 ± 0.0 0.2 ± 0.2 0.1 ± 0.1 0.0 ± 0.0 0.3 ± 0.1 0.1 ± 0.1 0.1 ± 0.0
Female 0.1 ± 0.1 0.1 ± 0.2 0.0 ± 0.0 0.1 ± 0.1 0.0 ± 0.0 0.0 ± 0.0 0.2 ± 0.1 0.0 ± 0.0 0.0 ± 0.0 0.2 ± 0.1 0.0 ± 0.0 0.0 ± 0.0
NE 109/L Male 1.2 ± 0.3 0.6 ± 0.2 0.6 ± 0.3 1.6 ± 0.5 1.2 ± 0.3** 0.8 ± 0.3 2.6 ± 0.8** 1.2 ± 0.5** 0.9 ± 0.2 2.2 ± 0.4** 1.5 ± 0.7** 1.1 ± 0.3
Female 0.7 ± 0.3 0.5 ± 0.2 0.3 ± 0.1 1.0 ± 0.7 0.6 ± 0.2 0.4 ± 0.1 1.1 ± 0.7 0.6 ± 0.1 0.4 ± 0.1 0.9 ± 0.3 0.5 ± 0.2 0.5 ± 0.1
EOS 109/L Male 0.0 ± 0.1 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.1 ± 0.1 0.0 ± 0.0 0.0 ± 0.0
Female 0.0 ± 0.1 0.0 ± 0.0 0.0 ± 0.0 0.1 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.1 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.1 0.0 ± 0.0 0.0 ± 0.0
BAS 109/L Male 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
Female 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
LYM % Male 77.7 ± 4.5 84.9 ± 0.9 86.7 ± 1.0 77.5 ± 5.2 80.7 ± 2.7** 83.4 ± 0.6** 72.8 ± 4.0 77.3 ± 2.4* 80.8 ± 1.8** 78.0 ± 4.7 75.9 ± 3.6** 79.0 ± 3.1**
Female 80.2 ± 6.1 80.0 ± 2.1 85.7 ± 0.7 80.3 ± 7.7 77.5 ± 3.7 83.9 ± 1.4* 79.8 ± 7.8 77.2 ± 2.3* 81.7 ± 2.6* 81.7 ± 6.2 78.9 ± 4.9 80.0 ± 2.0**
MON % Male 1.8 ± 0.3 1.1 ± 0.5 0.4 ± 0.1 1.9 ± 1.1 1.1 ± 0.4 0.5 ± 0.3 2.3 ± 0.7 1.4 ± 0.7 0.5 ± 0.2 2.7 ± 0.6 1.3 ± 0.5 1.1 ± 0.4
Female 1.5 ± 0.5 2.4 ± 4.3 0.3 ± 0.2 2.6 ± 0.5 0.9 ± 0.4 0.3 ± 0.3 2.7 ± 1.1 1.2 ± 0.6 0.6 ± 0.4 3.0 ± 0.6 0.9 ± 0.6 0.5 ± 0.3
NE % Male 19.5 ± 4.8 13.4 ± 0.7 12.3 ± 1.1 20.0 ± 4.8 17.6 ± 3.0** 15.8 ± 0.6 24.5 ± 4.0 20.6 ± 2.6* 18.1 ± 1.7 18.7 ± 4.3 22.0 ± 3.6** 19.3 ± 3.4
Female 16.8 ± 6.3 16.9 ± 4.4 13.8 ± 0.7 15.5 ± 7.9 20.7 ± 3.5 15.2 ± 1.5 16.6 ± 8.7 20.6 ± 2.7* 16.7 ± 2.6 14.2 ± 6.0 19.3 ± 4.1 18.7 ± 1.8
EOS % Male 0.7 ± 0.3 0.4 ± 0.3 0.4 ± 0.4 0 0.4 ± 0.3 0.3 ± 0.2 0.2 ± 0.1 0.3 ± 0.2 0.4 ± 0.3 0.4 ± 0.3 0.5 ± 0.2 0.5 ± 0.4 0.4 ± 0.2
Female 1.2 ± 0.2 0.5 ± 0.2 0.1 ± 0.1 1.0 ± 0.3 0.5 ± 0.2 0.5 ± 0.1 0.7 ± 0.5 0.7 ± 0.5 0.8 ± 0.6 0.8 ± 0.4 0.8 ± 0.5 0.5 ± 0.4
BAS % Male 0.3 ± 0.1 0.3 ± 0.2 0.2 ± 0.1 0.2 ± 0.2 0.3 ± 0.2 0.2 ± 0.1 0.1 ± 0.1 0.3 ± 0.2 0.1 ± 0.1 0.1 ± 0.1 0.3 ± 0.1 0.2 ± 0.0
Female 0.2 ± 0.2 0.3 ± 0.3 0.1 ± 0.1 0.5 ± 0.2 0.4 ± 0.3 0.1 ± 0.1 0.2 ± 0.3 0.2 ± 0.2 0.2 ± 0.3 0.3 ± 0.1 0.1 ± 0.2 0.2 ± 0.3
RET ‰ Male 11 ± 4 21 ± 5 10 ± 3 14 ± 6 18 ± 3 12 ± 2 16 ± 3* 18 ± 7 11 ± 4 14 ± 4 21 ± 5 11 ± 4
   Female 18 ± 4 21 ± 4 10 ± 3 19 ± 5 22 ± 4 17 ± 2 18 ± 4 18 ± 6 11 ± 3 14 ± 4 28 ± 7 10 ± 4
  1. Note: Red blood cell (RBC), hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular HGB (MCH), mean corpuscular HGB concentration (MCHC), red cell distribution width (RDW), platelets (PLT), mean platelet volume (MPV), platelet distribution width (PDW), white blood cell (WBC) counts, reticulocytes (RET), neutrophils (NE), lymphocytes (LYM), monocytes (MON), eosinophils (EOS), and basophils (BAS) prothrombin time (PT). Values are mean ± S.D. (n = 5 (4 weeks), 10 (26 weeks) or recovery (30 weeks)/sex/dose). * P < 0.05 & ** P < 0.01 compared with normal group.
Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us